0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fabry Disease Treatment Market by Treatment Type, End User, Distribution Channel, Route of Administration, Patient Type, Therapy Approach, Reimbursement Tier - Global Forecast to 2030- Product Image
Fabry Disease Treatment Market by Treatment Type, End User, Distribution Channel, Route of Administration, Patient Type, Therapy Approach, Reimbursement Tier - Global Forecast to 2030- Product Image
Sale

Fabry Disease Treatment Market by Treatment Type, End User, Distribution Channel, Route of Administration, Patient Type, Therapy Approach, Reimbursement Tier - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989675
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fabry Disease Treatment Market grew from USD 2.71 billion in 2024 to USD 2.94 billion in 2025. It is expected to continue growing at a CAGR of 8.50%, reaching USD 4.42 billion by 2030.

Introduction to the Evolving Fabry Disease Therapeutics Landscape

Fabry disease presents a multifaceted challenge that spans rare genetic pathology, chronic patient management, and evolving therapeutic frontiers. As a lysosomal storage disorder, it arises from alpha-galactosidase A deficiency, leading to intracellular accumulation of globotriaosylceramide and progressive organ damage. Historically, the treatment paradigm centered on enzyme replacement therapy, yet the arrival of novel modalities has ushered in a period of unprecedented dynamism. This introduction lays the groundwork for an executive synthesis of the transformative forces shaping treatment strategies, regulatory shifts, payer landscapes, and competitive dynamics.

Understanding this complex environment requires a holistic perspective that integrates clinical efficacy, patient quality of life, and economic sustainability. Regulatory approvals for chaperone molecules and early-stage gene therapies signal a potential paradigm shift, but they also introduce questions about accessibility, long-term safety, and value-based reimbursement. Consequently, stakeholders from biopharma innovators to healthcare providers and payers must align on evidence generation, distribution networks, and pricing mechanisms. In this context, the report offers an encyclopedic overview of the market’s current state, emerging trajectories, and actionable insights for decision-makers.

Transformative Dynamics Reshaping Fabry Disease Management

The Fabry disease treatment landscape is undergoing several transformative dynamics that extend far beyond incremental improvements. First, scientific breakthroughs in gene editing and vector design are moving therapies from palliation to potential cures, accelerating investment in AAV-based and lentiviral platforms. Simultaneously, molecular chaperones are optimizing endogenous enzyme function, offering an oral alternative that may reduce infusion burden and improve patient adherence.

Beyond science, payers and health systems are shifting toward value-based frameworks, demanding real-world evidence and outcomes-linked contracts. Payers in mature markets are forming alliances with manufacturers to pilot risk-sharing models, while reimbursement authorities are re-evaluating orphan drug designations under new cost-effectiveness guidelines. At the same time, supply chain innovations, including decentralized manufacturing and direct-to-patient distribution, are reshaping how therapies reach the bedside. Taken together, these trends reflect a holistic disruption in clinical, regulatory, and commercial dimensions, setting the stage for the next generation of treatment standards.

Projected Influence of US Tariffs on the Fabry Disease Market

The imposition of updated US tariffs in 2025 poses a complex set of implications for all stakeholders in the Fabry disease market. Tariff adjustments on imported active pharmaceutical ingredients and biologic components may elevate production costs, prompting manufacturers to re-examine internal pricing strategies. This cost inflation risks translating into higher out-of-pocket expenses for patients who rely on enzyme replacement infusions and substrate reduction therapies, unless mitigated by robust reimbursement safeguards.

Moreover, supply chain realignments could emerge as companies explore nearshoring or domestic manufacturing to buffer against tariff volatility. While these shifts may enhance supply security, they often entail significant capital expenditure, which could divert investment from research and development in novel gene therapies and chaperone molecules. Payers and policymakers will need to balance the protectionist intent of tariffs with the imperative of maintaining affordable access to life-saving treatments. Ultimately, the 2025 tariff landscape could catalyze strategic realignments across the value chain, influencing everything from raw material sourcing to patient affordability.

Insightful Segmentation Patterns Defining Treatment Preferences

Segmentation analysis reveals nuanced patterns that directly inform clinical strategies, commercial targeting, and payer negotiations. When viewed through the lens of treatment type, chaperone therapy-exemplified by migalastat-offers a compelling oral alternative to traditional enzyme replacement, while agalsidase alfa and agalsidase beta continue to underpin infusion-based regimens. At the same time, gene therapy efforts bifurcate into AAV-based and lentiviral-based vectors, each pursuing long-term correction in specialist centers, whereas substrate reduction candidates such as lucerastat and venglustat are positioning themselves as combination agents with established therapies.

End users further refine market dynamics: home healthcare providers now deliver infusions and oral regimens directly to patients, alleviating hospital congestion, while hospitals and specialty clinics remain critical for complex interventions and gene therapy administration. Distribution channels underscore evolving patient preferences, with hospital and specialty pharmacies maintaining strong presence for high-acuity therapies, even as online pharmacies gain traction for oral and self-administered treatments. Route of administration delineates between intravenous infusions conducted in clinical settings and convenient oral regimens that may enhance adherence. Patient type categorization into adult and pediatric segments sheds light on differing safety profiles and dosing considerations. Meanwhile, therapy approach contrasts curative ambitions of gene-based platforms against the palliative focus of enzyme and substrate reduction therapies. Finally, reimbursement tier segmentation highlights the interplay between government insurance, private payers, and out-of-pocket funding, emphasizing the need for tailored access strategies to minimize financial barriers across payer cohorts.

Regional Variations Illuminating Fabry Disease Treatment Demand

Regional insights reveal that the Americas sustain the largest share of Fabry disease treatment investments, driven by early adoption of enzyme replacement therapies and expanding reimbursement for chaperone molecules. North America in particular benefits from streamlined regulatory pathways and well-established rare disease consortia, while Latin America shows increasing interest in capacity building for home infusion services.

Across Europe, Middle East & Africa, heterogeneous healthcare systems create pockets of high innovation-Western Europe leads in gene therapy clinical trials and value-based pricing pilots, whereas emerging markets in the Middle East and North Africa are gradually integrating rare disease centers of excellence. Reimbursement complexities vary significantly, necessitating region-specific market access blueprints that account for national health technology assessments and co-pay structures.

Asia-Pacific registers rapid growth in oral therapeutic uptake, especially in countries with large patient populations and rising healthcare expenditure. China’s nascent reimbursement reforms and Japan’s orphan drug incentives are catalyzing local and global partnerships. Meanwhile, Australia and Southeast Asia are investing in patient registries and telehealth infrastructure to streamline diagnosis and treatment delivery across distributed geographies.

Competitive Landscape: Pioneers and Emerging Innovators

Leading pharmaceutical players continue to shape market trajectories through differentiated portfolios and strategic collaborations. Established companies maintain momentum in enzyme replacement therapy with well-characterized safety profiles and robust manufacturing networks, securing long-term supply commitments with healthcare providers. Meanwhile, specialty biotechs are advancing next-generation gene therapy candidates, leveraging optimizing vector design and targeted delivery to tissues most affected by alpha-galactosidase A deficiency.

Partnerships between large pharma and pioneering biotech firms accelerate clinical development and broaden geographic reach, pooling regulatory expertise with innovative science. Several companies are also forging alliances with contract development and manufacturing organizations to scale gene therapy production. In parallel, emerging entrants focused on substrate reduction and chaperone therapy are carving out niche positions by demonstrating improved patient adherence and reduced infusion frequency. Competitive differentiation increasingly hinges on real-world evidence, patient-centric service models, and integrated digital solutions that enhance long-term monitoring and support.

Strategic Recommendations to Accelerate Market Leadership

Industry leaders should prioritize investment in scalable gene therapy platforms, focusing on vector optimization and manufacturing efficiencies that can reduce cost per patient and enable curative outcomes. Simultaneously, expanding evidence generation for chaperone and substrate reduction therapies in real-world settings will strengthen payer negotiations and support outcomes-based contracting models. Early engagement with health technology assessment bodies across major markets can expedite access pathways and clarify evidence expectations for novel modalities.

Collaborating closely with home healthcare networks and specialty pharmacies will enhance patient adherence and satisfaction while alleviating logistical burdens on hospitals. Developing robust patient support programs-encompassing education, digital adherence tools, and financial assistance-will differentiate offerings and mitigate access challenges. Finally, forging cross-sector alliances with diagnostic specialists, data analytics providers, and payers will foster integrated care pathways that improve diagnostic timelines and optimize therapeutic sequencing.

Rigorous Methodology Underpinning Our Market Analysis

This analysis integrates a mixed-methods approach, commencing with comprehensive secondary research across peer-reviewed journals, regulatory filings, and industry databases. We conducted qualitative interviews with key opinion leaders in clinical genetics, patient advocacy representatives, and payer decision-makers to capture evolving treatment paradigms and reimbursement hurdles. Quantitative data collection involved synthesizing clinical trial registries, sales data from leading research databases, and anonymized insurance claim records to validate market trends and segmentation dynamics.

To ensure analytical rigor, data triangulation techniques were employed, cross-checking findings across multiple independent sources. Sensitivity analyses quantified the impact of potential tariff scenarios, while thematic coding distilled strategic imperatives from expert interviews. All insights underwent peer review by a panel of clinical, regulatory, and commercial strategy specialists to verify accuracy and relevance. Ethical considerations were observed throughout, adhering to confidentiality protocols and informed consent practices in primary research activities.

Synthesis of Key Insights and Strategic Implications

In synthesizing the transformative shifts, tariff implications, segmentation patterns, regional nuances, and competitive dynamics, this executive summary presents a cohesive narrative of the Fabry disease treatment landscape. Scientific advancements in gene editing and molecular chaperones pave the way for potentially curative treatments, while payers drive demand for robust real-world evidence and value-based contracting. Tariff changes introduce new cost variables that may accelerate localization of manufacturing and influence pricing negotiations.

Segmentation analysis provides actionable insights into how treatment type, end user, distribution channel, route of administration, patient demographics, therapy approach, and reimbursement tier intersect to shape market opportunities. Regional perspectives highlight differential adoption curves and regulatory frameworks across the Americas, Europe, Middle East & Africa, and Asia-Pacific, reinforcing the need for tailored access strategies. Competitive intelligence underscores the importance of strategic partnerships, innovative pipelines, and patient-centric service models. Together, these elements establish a strategic roadmap for industry leaders seeking to navigate complexity and drive sustainable growth in Fabry disease therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chaperone Therapy
      • Migalastat
    • Enzyme Replacement Therapy
      • Agalsidase Alfa
      • Agalsidase Beta
    • Gene Therapy
      • Aav Based
      • Lentiviral Based
    • Substrate Reduction Therapy
      • Lucerastat
      • Venglustat
  • End User
    • Home Healthcare
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • Route Of Administration
    • Intravenous
    • Oral
  • Patient Type
    • Adult
    • Pediatric
  • Therapy Approach
    • Curative
    • Palliative
  • Reimbursement Tier
    • Government Insurance
    • Out-Of-Pocket
    • Private Insurance
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc.
  • Protalix BioTherapeutics, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Idorsia Pharmaceuticals Ltd.
  • Nippon Shinyaku Co., Ltd.
  • Zambon S.p.A.
  • Swedish Orphan Biovitrum AB
  • Orphazyme ApS

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fabry Disease Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chaperone Therapy
8.2.1. Migalastat
8.3. Enzyme Replacement Therapy
8.3.1. Agalsidase Alfa
8.3.2. Agalsidase Beta
8.4. Gene Therapy
8.4.1. Aav Based
8.4.2. Lentiviral Based
8.5. Substrate Reduction Therapy
8.5.1. Lucerastat
8.5.2. Venglustat
9. Fabry Disease Treatment Market, by End User
9.1. Introduction
9.2. Home Healthcare
9.3. Hospitals
9.4. Specialty Clinics
10. Fabry Disease Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.5. Specialty Pharmacy
11. Fabry Disease Treatment Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Fabry Disease Treatment Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Fabry Disease Treatment Market, by Therapy Approach
13.1. Introduction
13.2. Curative
13.3. Palliative
14. Fabry Disease Treatment Market, by Reimbursement Tier
14.1. Introduction
14.2. Government Insurance
14.3. Out-Of-Pocket
14.4. Private Insurance
15. Americas Fabry Disease Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Fabry Disease Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Fabry Disease Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Sanofi S.A.
18.3.2. Takeda Pharmaceutical Company Limited
18.3.3. Amicus Therapeutics, Inc.
18.3.4. Protalix BioTherapeutics, Inc.
18.3.5. Chiesi Farmaceutici S.p.A.
18.3.6. Idorsia Pharmaceuticals Ltd.
18.3.7. Nippon Shinyaku Co., Ltd.
18.3.8. Zambon S.p.A.
18.3.9. Swedish Orphan Biovitrum AB
18.3.10. Orphazyme ApS
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. FABRY DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. FABRY DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2024 VS 2030 (%)
FIGURE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FABRY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY MIGALASTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AGALSIDASE ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AAV BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY LUCERASTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY VENGLUSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CURATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 72. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 73. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 78. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 89. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 135. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 136. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 137. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 138. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 139. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 140. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 145. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 146. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 149. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 156. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 168. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 170. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 171. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 172. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 173. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 178. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 179. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 181. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 182. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 183. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 184. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 189. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 223. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 225. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 226. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 227. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 228. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 233. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 245. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 247. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 248. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 249. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 250. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 255. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 256. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 258. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 259. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 260. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 261. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 266. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 289. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 291. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 292. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 293. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 294. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 299. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 300. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 302. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 303. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 304. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 305. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 309. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY THERAPY APPROACH, 2018-2030 (USD MILLION)
TABLE 310. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY REIMBURSEMENT TIER, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 316

Companies Mentioned

The companies profiled in this Fabry Disease Treatment market report include:
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics, Inc.
  • Protalix BioTherapeutics, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Idorsia Pharmaceuticals Ltd.
  • Nippon Shinyaku Co., Ltd.
  • Zambon S.p.A.
  • Swedish Orphan Biovitrum AB
  • Orphazyme ApS

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.42 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
EUR$5,950USDGBP
Fabry Disease Treatment - Global Strategic Business Report - Product Image

Fabry Disease Treatment - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
EUR$5,850USDGBP
Fabry Disease Market Report by Type, Diagnosis and Treatment, End User, and Region 2025-2033 - Product Image

Fabry Disease Market Report by Type, Diagnosis and Treatment, End User, and Region 2025-2033

  • Report
  • 130 Pages
  • Global
From
EUR$2,999USDGBP
Fabry Disease Treatment Market Report 2025 - Product Image

Fabry Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Fabry Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
EUR$4,500USDGBP

About the Fabry Disease Drug Market

Fabry Disease is a rare, inherited disorder caused by the deficiency of an enzyme called alpha-galactosidase A. This deficiency leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body's cells, resulting in a wide range of symptoms. Endocrine and Metabolic Disorders Drugs are used to treat Fabry Disease, including enzyme replacement therapy (ERT) and chaperone therapy. ERT is the most common treatment, and involves the administration of a recombinant form of the missing enzyme. Chaperone therapy is a newer treatment option, and involves the use of small molecules to help the body's cells process GL-3. The Fabry Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. Companies in the market include Sanofi, Amicus Therapeutics, Shire, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more